Synlogic (NASDAQ:SYBX) Trading Down 0.7% – Here’s What Happened

Synlogic, Inc. (NASDAQ:SYBX)’s share price traded down 0.7% during trading on Thursday . The company traded as low as $1.44 and last traded at $1.52. 103,418 shares were traded during trading, an increase of 100% from the average session volume of 51,819 shares. The stock had previously closed at $1.53.

Synlogic Trading Down 1.3 %

The stock has a market cap of $17.55 million, a price-to-earnings ratio of -0.36 and a beta of 0.83. The firm’s 50 day moving average is $1.43 and its two-hundred day moving average is $1.50.

Synlogic (NASDAQ:SYBX) last released its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.17. Synlogic had a negative net margin of 2,284.65% and a negative return on equity of 207.84%. As a group, equities analysts expect that Synlogic, Inc. will post -2.71 EPS for the current fiscal year.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.